Allarity Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Allarity Therapeutics, Inc. has filed its 2023 Form 10-K, detailing its financial and operational status.</b>

AI Summary

Allarity Therapeutics, Inc. (ALLR) filed a Annual Report (10-K) with the SEC on March 8, 2024. Allarity Therapeutics, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and headquartered in Boston, MA. Its common stock trades on The Nasdaq Stock Market LLC under the symbol ALLR. Allarity Therapeutics is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. The filing confirms the company has submitted all required reports for the preceding 12 months and has been subject to filing requirements for the past 90 days.

Why It Matters

For investors and stakeholders tracking Allarity Therapeutics, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Allarity Therapeutics' financial performance, business operations, and risk factors for the fiscal year 2023, crucial for investors to assess the company's current standing. As a smaller reporting company and emerging growth company, this filing offers insights into its regulatory compliance and disclosure practices, which are important for understanding its market position and future prospects.

Risk Assessment

Risk Level: low — Allarity Therapeutics, Inc. shows low risk based on this filing. The filing is a standard annual report (10-K) and does not contain immediate negative news or significant changes, indicating a routine disclosure.

Analyst Insight

Investors should review the detailed financial statements and risk factors within the 10-K to understand Allarity Therapeutics' performance and outlook.

Key Numbers

• 2023 — Fiscal Year End (Reported fiscal year)
• December 31 — Fiscal Year End Date (Specific date for the fiscal year end)
• 001-41160 — Commission File Number (SEC identifier for the company)
• 24 School Street, 2nd Floor, Boston, MA 02108 — Business Address (Principal executive offices location)

Key Players & Entities

• Allarity Therapeutics, Inc. (company) — Filer name
• 2023 (date) — Fiscal year end
• December 31 (date) — Fiscal year end
• Boston, MA (location) — Business address
• ALLR (ticker) — Trading symbol
• The Nasdaq Stock Market LLC (company) — Exchange
• Delaware (location) — State of incorporation
• 001-41160 (other) — Commission file number

FAQ

Industry Context

Allarity Therapeutics operates in the pharmaceutical preparations industry, focusing on developing and commercializing therapeutic solutions.

Regulatory Implications

The company is subject to standard SEC reporting requirements for public companies, including the annual filing of Form 10-K.

What Investors Should Do

1. Review the financial statements and management's discussion and analysis in the 10-K for detailed performance metrics.
2. Analyze the risk factors section to understand potential challenges and uncertainties facing the company.
3. Monitor future SEC filings for updates on the company's strategic initiatives and financial health.

Key Dates

• 2024-03-08: 10-K Filing — Filing of the annual report for the fiscal year ended December 31, 2023.

Year-Over-Year Comparison

This is the annual report for the fiscal year ended December 31, 2023, following previous filings which would include quarterly reports and potentially prior annual reports.

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Market
• $4,900,000 — ly due and payable in the amount of USD $4,900,000 plus interest; on December 8, 2023, J
• $2,500,000 — the stockholders' equity requirement of $2,500,000 will result in immediate delisting, sub
• $1 — ur Common Stock has closed at less than $1 per share over the previous 30 consecut
• $250 million — ock held by non-affiliates is less than $250 million or (ii) our annual revenue was less tha
• $100 million — r (ii) our annual revenue was less than $100 million during the most recently completed fisc
• $700 million — ock held by non-affiliates is less than $700 million. To the extent we take advantage of suc

Filing Documents

• ea0200752-10k_allarity.htm (10-K) — 3361KB
• ea0200752ex10-63_allarity.htm (EX-10.63) — 127KB
• ea0200752ex21_allarity.htm (EX-21) — 3KB
• ea0200752ex31-1_allarity.htm (EX-31.1) — 10KB
• ea0200752ex31-2_allarity.htm (EX-31.2) — 10KB
• ea0200752ex32-1_allarity.htm (EX-32.1) — 4KB
• ea0200752ex32-2_allarity.htm (EX-32.2) — 4KB
• ea0200752ex97_allarity.htm (EX-97.1) — 48KB
• image_001.jpg (GRAPHIC) — 25KB
• image_002.jpg (GRAPHIC) — 25KB
• image_003.jpg (GRAPHIC) — 26KB
• image_004.jpg (GRAPHIC) — 32KB
• image_005.jpg (GRAPHIC) — 25KB
• image_006.jpg (GRAPHIC) — 19KB
• image_007.jpg (GRAPHIC) — 20KB
• image_008.jpg (GRAPHIC) — 16KB
• image_009.jpg (GRAPHIC) — 20KB
• image_010.jpg (GRAPHIC) — 13KB
• image_011.jpg (GRAPHIC) — 13KB
• image_012.jpg (GRAPHIC) — 22KB
• image_013.jpg (GRAPHIC) — 10KB
• image_014.jpg (GRAPHIC) — 11KB
• image_015.jpg (GRAPHIC) — 30KB
• image_016.jpg (GRAPHIC) — 16KB
• image_017.jpg (GRAPHIC) — 19KB
• image_018.jpg (GRAPHIC) — 25KB
• image_019.jpg (GRAPHIC) — 28KB
• ex10-63_001.jpg (GRAPHIC) — 30KB
• 0001213900-24-020864.txt (&nbsp;) — 13628KB
• allr-20231231.xsd (EX-101.SCH) — 107KB
• allr-20231231_cal.xml (EX-101.CAL) — 44KB
• allr-20231231_def.xml (EX-101.DEF) — 478KB
• allr-20231231_lab.xml (EX-101.LAB) — 848KB
• allr-20231231_pre.xml (EX-101.PRE) — 484KB
• ea0200752-10k_allarity_htm.xml (XML) — 1498KB

BUSINESS

BUSINESS 1 ITEM 1A. RISK FACTORS 79 ITEM 1B. UNRESOLVED STAFF COMMENTS 138 ITEM 1C. CYBERSECURITY 138 ITEM 2.

PROPERTIES

PROPERTIES 138 ITEM 3. LEGAL PROCEEDINGS 139 ITEM 4. MINE SAFETY DISCLOSURES 139 PART II ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 139 ITEM 6. [RESERVED] 140 ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 140 ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 151 ITEM 8. FINANCIAL 151 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 152 ITEM 9A CONTROLS AND PROCEDURES 153 ITEM 9B. OTHER INFORMATION 154 ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTION THAT PREVENTS INSPECTIONS 154 PART III 155 ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 155 ITEM 11. EXECUTIVE COMPENSATION 155 ITEM 12. SECURITY 155 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE 155 ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 155 PART IV 156 ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 156 ITEM 16. FORM 10-K SUMMARY 159

SIGNATURES

SIGNATURES 160 FINANCIAL F-1 When used herein, unless the context requires otherwise, references to the "Company," "we," "our" and "us" refer to Allarity Therapeutics, Inc., a Delaware corporation. i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (the "Annual Report") contains forward-looking statements that involve substantial risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act, Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements, other than statements of historical fact, contained in this Annual Report. including statements regarding our strategy, future preclinical studies and clinical trials, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," will" "would," or the negative of these words or other similar expressions are intended to identify forward-looking statements, although not all forward-looking and subject to risks and uncertainties. If one or more of these risk factors or uncertainties materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Furthermore, we operate in a competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impac

View Full Filing

View this 10-K filing on SEC EDGAR